Abstract:
:Alipogene tiparvovec (Glybera®; AMT-011, AAV1-LPL(S447X)) is an adeno-associated virus serotype 1-based gene therapy for adult patients with familial lipoprotein lipase (LPL) deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions. It is administered as a one-time series of intramuscular injections in the legs. LPLD, a rare autosomal recessive disorder, results in hyperchylomicronaemia and severe hypertriglyceridaemia, which in turn, are associated with an increased risk of clinical complications, the most debilitating of which is recurrent severe and potentially life-threatening pancreatitis. In clinical studies (n = 27 patients), one-time administration of alipogene tiparvovec was associated with significant reductions in plasma triglyceride levels during the 12 or 14 week study period post administration. Although triglyceride levels returned to pre-treatment levels within 16-26 weeks after administration, patients had sustained improvements in postprandial chylomicron metabolism, with sustained expression of functional copies of the LPL (S477X) gene and of biologically active LPL in skeletal muscle. Moreover, after up to 6 years' follow-up post administration, there were clinically relevant reductions in the incidence of documented pancreatitis and acute abdominal pain events consistent with pancreatitis. Alipogene tiparvovec was generally well tolerated, with most adverse events being localized, transient, mild to moderate injection-site reactions. This article reviews the pharmacology of alipogene tiparvovec and its efficacy and safety in adults with LPLD.
journal_name
Drugsjournal_title
Drugsauthors
Scott LJdoi
10.1007/s40265-014-0339-9subject
Has Abstractpub_date
2015-02-01 00:00:00pages
175-82issue
2eissn
0012-6667issn
1179-1950journal_volume
75pub_type
杂志文章,评审相关文献
DRUGS文献大全abstract::A gradual rise in drug-resistant trends among Gram-negative organisms, especially carbapenem-resistant (CR) Enterobacteriaceae (CRE), CR-Pseudomonas aeruginosa, and extensively-drug-resistant (XDR) Acinetobacter baumannii, poses an enormous threat to healthcare systems worldwide. In the last decade, many pharmaceutica...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01112-1
更新日期:2019-05-01 00:00:00
abstract::All 27 EU member states and another seven countries participate in the European Surveillance of Antimicrobial Consumption (ESAC) project. ESAC carried out three hospital point-prevalence surveys on antimicrobial use. Point-prevalence surveys linked antimicrobial use to indication and also assessed dosing using a stand...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/11591180-000000000-00000
更新日期:2011-04-16 00:00:00
abstract::Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199753050-00012
更新日期:1997-05-01 00:00:00
abstract::Induction of labour, defined as stimulation of uterine contractions before the spontaneous onset of labour, is indicated when the condition of the mother or fetus precludes awaiting the onset of spontaneous labour. In current medical practice, induction of labour comprises 2 phases: cervical priming and induction of c...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199754010-00005
更新日期:1997-07-01 00:00:00
abstract::Along with nausea and vomiting, postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anaesthesia. The distinguishing factor during electromyogram recordings between patients with postanaesthetic shivering and shivering in fully awake patients is the existence of clo...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200161150-00004
更新日期:2001-01-01 00:00:00
abstract::The popularity of antidepressants in the treatment of insomnia is not supported by a large amount of convincing data, but rather by opinions and beliefs of the prescribing physicians on the advantages of these agents compared with drugs acting on the benzodiazepine receptor or other drugs used for the treatment of ins...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/0003495-200868170-00001
更新日期:2008-01-01 00:00:00
abstract::The allergic reaction to a specific antigen is characterised by a series of complex immunological processes consisting of an early specific immune response and a late inflammatory reaction. The release of active substances (principally histamine) from cytoplasmic granules of mast cells and basophils in response to ant...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199600521-00003
更新日期:1996-01-01 00:00:00
abstract::Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination therapy with metformin, a sulfonylurea, a thiazolidinedione, or insulin (with or without metformin) for the treatment of adult patients with typ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/11208160-000000000-00000
更新日期:2012-01-22 00:00:00
abstract::Crizotinib (Xalkori(®)) is an orally active, small molecule inhibitor of multiple receptor tyrosine kinases, including anaplastic lymphoma kinase (ALK), c-Met/hepatocyte growth factor receptor and c-ros oncogene 1. In the EU, crizotinib has been conditionally approved for the treatment of adults with previously treate...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0142-z
更新日期:2013-12-01 00:00:00
abstract::Cardiovascular disease continues to be the principal cause of death in Western countries. Epidemiological studies have repeatedly demonstrated a striking relationship between blood pressure and the risk of cardiovascular disease in that those with the highest levels of blood pressure are at the greatest risk for subse...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198600314-00003
更新日期:1986-01-01 00:00:00
abstract::The optimal treatment of pain requires an understanding of the mechanisms involved. Pain is a sensory end-point that can be generated by a number of dissimilar processes. Consequently, the concept of treating pain as a unitary symptom is obsolete. The mechanisms responsible for specific types of pain need to be unders...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199400475-00003
更新日期:1994-01-01 00:00:00
abstract::25 patients have been included in a randomised trial aimed to compare prehospital and hospital administration of anisoylated plasminogen streptokinase activator complex (AP-SAC). Patients were first seen, at home, by a noncardiologist doctor working in a mobile-care unit and were then evaluated for entry into the stud...
journal_title:Drugs
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.2165/00003495-198700333-00042
更新日期:1987-01-01 00:00:00
abstract::Increases in cancer diagnosis have tremendous negative impacts on patients and their families, and major societal and economic costs. The beneficial effect of chemotherapeutic agents on tumor suppression comes with major unwanted side effects such as weight and hair loss, nausea and vomiting, and neuropathic pain. Che...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01132-x
更新日期:2019-06-01 00:00:00
abstract::As a symptom of an underlying condition, cough is one of the most common reasons patients see physicians. To the majority, a cough means that 'something is wrong' and it causes exhaustion and/or self-consciousness. Patients find these reasons as well as effects on lifestyle, fear of cancer and/or AIDS or tuberculosis ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199346010-00006
更新日期:1993-07-01 00:00:00
abstract::The sensitivity to cefotaxime and amikacin of 14,272 Gram-negative bacilli (Enterobacteriaceae and non-fermenting Gram-negative bacilli) isolated from clinical samples was studied during the period 1980 to 1985. The minimum inhibitory concentration (MIC) was determined by means of diffusion in agar. Strains were consi...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-198800352-00003
更新日期:1988-01-01 00:00:00
abstract::The currently available, most frequently used disease-modifying antirheumatic drugs (DMARDs) include auranofin, azathioprine, D-penicillamine, gold sodium thiomalate, hydroxychloroquine, methotrexate (amethopterin) and sulphasalazine. Controlled trials of these agents are reviewed to compare their relative efficacy an...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199039010-00003
更新日期:1990-01-01 00:00:00
abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0064-9
更新日期:2013-06-01 00:00:00
abstract::Alectinib (Alecensa(®)) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase (ALK). Alectinib is approved for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in Japan, where it has been given orphan ...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0329-y
更新日期:2015-01-01 00:00:00
abstract::Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide. Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents are not effective against many strains, and carbapenems have played an important role in therapy. Recent trends show many infections are cau...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-014-0267-8
更新日期:2014-08-01 00:00:00
abstract::Pancreatic islet transplantation as a cell-based treatment for diabetes mellitus has been pursued for over quarter of a century, ever since the first successful use of this approach to cure diabetes mellitus in rodents in the 1970s. However, even though autoislet intrahepatic transplantation in patients with chronic p...
journal_title:Drugs
pub_type: 杂志文章
doi:10.2165/00003495-200161140-00001
更新日期:2001-01-01 00:00:00
abstract::Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they eff...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200868070-00004
更新日期:2008-01-01 00:00:00
abstract::Hypertension in pregnancy has implications for both maternal and fetal welfare. Extrapolation from concepts of mechanisms operating in hypertension in general to pregnancy-related hypertension is not justified. In the latter, the major features are a hyper-adrenergic state, plasma volume reduction and an increased sys...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198428020-00005
更新日期:1984-08-01 00:00:00
abstract::Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-019-01103-2
更新日期:2019-05-01 00:00:00
abstract::The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenatide belongs to a class of GLP-1 compounds designed to mimic the endogenous hormone GLP-1. Native GLP-1 stimulates insulin...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-013-0033-3
更新日期:2013-03-01 00:00:00
abstract::Alemtuzumab (Lemtrada®) is an anti-CD52 monoclonal antibody approved in the EU for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS). In phase 3 trials in patients with active RRMS, intravenous alemtuzumab was more effective than subcutaneous interferon β-1a in terms of decreasing relapse ra...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-020-01437-2
更新日期:2021-01-01 00:00:00
abstract::Torasemide (torsemide) is a high-ceiling loop diuretic which acts on the thick ascending limb of the loop of Henle to promote rapid and marked excretion of water, sodium and chloride. Like furosemide (frusemide), its major site of action is from the luminal side of the cell. Torasemide is at least twice as potent as f...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199141010-00008
更新日期:1991-01-01 00:00:00
abstract::Cytotoxic chemotherapy plays a key role in the treatment of carcinoma for thousands of patients annually who either present with metastatic disease or relapse after surgical excision of apparently localised disease. Unfortunately, there is such a wide range of responsiveness to drug therapy within individual tumour ty...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-198326050-00004
更新日期:1983-11-01 00:00:00
abstract::Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-200060050-00002
更新日期:2000-11-01 00:00:00
abstract::Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and diseas...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.1007/s40265-017-0860-8
更新日期:2018-01-01 00:00:00
abstract::Cidofovir is a nucleotide analogue which inhibits viral DNA polymerase and is effective against human cytomegalovirus (CMV) infection. It is phosphorylated to its active form by cellular enzymes. With the long intracellular half-life of its metabolites, cidofovir can be administered weekly during induction and every o...
journal_title:Drugs
pub_type: 杂志文章,评审
doi:10.2165/00003495-199652020-00006
更新日期:1996-08-01 00:00:00